LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 3 | G08 | 72 | hr | 1476 | 1201 | 3694 | 0.3251 | -0.1244 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 1 | F02 | 72 | hr | 1476 | 1032 | 3694 | 0.2794 | -0.2006 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 2 | F02 | 72 | hr | 1476 | 1029 | 3694 | 0.2786 | -0.2019 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 3 | F02 | 72 | hr | 1476 | 1062 | 3694 | 0.2875 | -0.1870 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 1 | G02 | 72 | hr | 1476 | 769 | 3694 | 0.2082 | -0.3192 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 2 | G02 | 72 | hr | 1476 | 1003 | 3694 | 0.2715 | -0.2136 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 3 | G02 | 72 | hr | 1476 | 784 | 3694 | 0.2122 | -0.3124 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 1 | P14 | 72 | hr | 1476 | 2722 | 3694 | 0.7369 | 0.5616 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 2 | P14 | 72 | hr | 1476 | 2969 | 3694 | 0.8037 | 0.6730 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 3 | P14 | 72 | hr | 1476 | 2912 | 3694 | 0.7883 | 0.6473 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 1 | A08 | 72 | hr | 1476 | 1687 | 3694 | 0.4567 | 0.0948 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 2 | A08 | 72 | hr | 1476 | 1602 | 3694 | 0.4337 | 0.0565 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 3 | A08 | 72 | hr | 1476 | 1497 | 3694 | 0.4053 | 0.0091 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 1 | I08 | 72 | hr | 1476 | 3366 | 3694 | 0.9112 | 0.8521 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 2 | I08 | 72 | hr | 1476 | 2945 | 3694 | 0.7972 | 0.6622 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 3 | I08 | 72 | hr | 1476 | 3128 | 3694 | 0.8468 | 0.7447 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 1476 | 1800 | 3694 | 0.4873 | 0.1458 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 1476 | 1803 | 3694 | 0.4881 | 0.1472 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 1476 | 1923 | 3694 | 0.5206 | 0.2013 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 1 | P08 | 72 | hr | 1476 | 2346 | 3694 | 0.6351 | 0.3920 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 2 | P08 | 72 | hr | 1476 | 2320 | 3694 | 0.6280 | 0.3803 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 3 | P08 | 72 | hr | 1476 | 2225 | 3694 | 0.6023 | 0.3375 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 1476 | 2165 | 3694 | 0.5861 | 0.3104 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 2 | D02 | 72 | hr | 1476 | 2081 | 3694 | 0.5633 | 0.2725 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 3 | D02 | 72 | hr | 1476 | 2113 | 3694 | 0.5720 | 0.2870 |